Fosun Pharma Grants 0.73 Million A-Share Options at RMB 27.93 Each Under 2025 Scheme

Bulletin Express

Aug 28

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) disclosed that its board approved a reserved grant of approximately 0.73 million A-Share options on 28 August 2026. The grant, made under the company’s 2025 A-Share Option Scheme, covers 100 eligible participants and represents about 0.0272% of Fosun Pharma’s total issued share capital.

Each option carries an exercise price of RMB 27.93 per A-share. Several grantees are classified as connected persons at the subsidiary level, rendering the allocation a connected transaction under Hong Kong Listing Rule 14A. Nevertheless, all applicable percentage ratios are below 1%, so the transaction qualifies for exemptions from shareholders’ approval, annual review, and further disclosure requirements.

The decision was approved by the board on the same day as the announcement, with Chairman Chen Yuqing signing on behalf of the board. No additional financial terms or performance conditions were detailed in the filing.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1176172521"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1176172521\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1176172521?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-28 18:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1176172521","market":"us","top_or_hot":-1,"title":"Fosun Pharma Grants 0.73 Million A-Share Options at RMB 27.93 Each Under 2025 Scheme","media":"Bulletin Express","content":"<p>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) disclosed that its board approved a reserved grant of approximately 0.73 million A-Share options on 28 August 2026. The grant, made under the company’s 2025 A-Share Option Scheme, covers 100 eligible participants and represents about 0.0272% of Fosun Pharma’s total issued share capital.</p>\n<p>Each option carries an exercise price of RMB 27.93 per A-share. Several grantees are classified as connected persons at the subsidiary level, rendering the allocation a connected transaction under Hong Kong Listing Rule 14A. Nevertheless, all applicable percentage ratios are below 1%, so the transaction qualifies for exemptions from shareholders’ approval, annual review, and further disclosure requirements.</p>\n<p>The decision was approved by the board on the same day as the announcement, with Chairman Chen Yuqing signing on behalf of the board. No additional financial terms or performance conditions were detailed in the filing.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fosun Pharma Grants 0.73 Million A-Share Options at RMB 27.93 Each Under 2025 Scheme</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFosun Pharma Grants 0.73 Million A-Share Options at RMB 27.93 Each Under 2025 Scheme\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-08-28 18:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) disclosed that its board approved a reserved grant of approximately 0.73 million A-Share options on 28 August 2026. The grant, made under the company’s 2025 A-Share Option Scheme, covers 100 eligible participants and represents about 0.0272% of Fosun Pharma’s total issued share capital.</p>\n<p>Each option carries an exercise price of RMB 27.93 per A-share. Several grantees are classified as connected persons at the subsidiary level, rendering the allocation a connected transaction under Hong Kong Listing Rule 14A. Nevertheless, all applicable percentage ratios are below 1%, so the transaction qualifies for exemptions from shareholders’ approval, annual review, and further disclosure requirements.</p>\n<p>The decision was approved by the board on the same day as the announcement, with Chairman Chen Yuqing signing on behalf of the board. No additional financial terms or performance conditions were detailed in the filing.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02196","symbol_name":"复星医药","start_time":0,"source_url":"","article_id":"1176172521","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1176172521","pubTimestamp":1787913840,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) disclosed that its board approved a reserved grant of approximately 0.73 million A-Share options on 28 August 2026. The grant, made...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02196":"复星医药"},"translate_title":"复星医药2025年计划授予73万份A股期权，每份27.93元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02196":1},"content_text":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) disclosed that its board approved a reserved grant of approximately 0.73 million A-Share options on 28 August 2026. The grant, made under the company’s 2025 A-Share Option Scheme, covers 100 eligible participants and represents about 0.0272% of Fosun Pharma’s total issued share capital.\nEach option carries an exercise price of RMB 27.93 per A-share. Several grantees are classified as connected persons at the subsidiary level, rendering the allocation a connected transaction under Hong Kong Listing Rule 14A. Nevertheless, all applicable percentage ratios are below 1%, so the transaction qualifies for exemptions from shareholders’ approval, annual review, and further disclosure requirements.\nThe decision was approved by the board on the same day as the announcement, with Chairman Chen Yuqing signing on behalf of the board. No additional financial terms or performance conditions were detailed in the filing.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}